1. Slaby, O., M. Sachlova, V. Brezkova, R. Hezova and A. Kovarikova et al., 2013. Identification of microRNAs regulated by isothiocyanates and association of polymorphisms inside their target sites with risk of sporadic colorectal cancer. Nutr. Cancer, 65: 247-254.
   CrossRef  |  PubMed  |  
2. Slaby, O., 2013. MiR-190 leads to aggressive phenotype of neuroblastoma through indirect activation of TrkB pathway. Med. Hypotheses, 80: 325-326.
   CrossRef  |  
3. Sevcikova, S., L. Kubiczkova, L. Sedlarikova, O. Slaby and R. Hajek, 2013. Serum miR-29a as a marker of multiple myeloma. Leukemia Lymphoma, 54: 189-191.
   CrossRef  |  
4. Redova, M., J. Sana and O. Slaby, 2013. Circulating miRNAs as new blood-based biomarkers for solid cancers. Future Oncol., 9: 387-402.
   CrossRef  |  PubMed  |  
5. Redova, M., A. Poprach, A. Besse, R. Iliev and J. Nekvindovan et al., 2013. MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma. Tumour Biol., 34: 481-491.
   CrossRef  |  
6. Novak, J., J. Vinklarek, J. Bienertova‐Vasku and O. Slaby, 2013. MicroRNAs involved in skeletal muscle development and their roles in rhabdomyosarcoma pathogenesis. Pediatr. Blood Cancer, 60: 1739-1746.
   CrossRef  |  
7. Mlcochova, J., P. Faltejskova, R. Nemecek, M. Svoboda and O. Slaby, 2013. MicroRNAs targeting EGFR signalling pathway in colorectal cancer. J. Cancer Res. Clin. Oncol., 139: 1615-1624.
   CrossRef  |  
8. Bienertova-Vasku, J., P. Mazanek, R. Hezova, A. Curdova and J. Nekvindova et al., 2013. Extension of microRNA expression pattern associated with high-risk neuroblastoma. Tumour Biol., 34: 2315-2319.
   CrossRef  |  
9. Bienertova-Vasku, J., J. Sana and O. Slaby, 2013. The role of microRNAs in mitochondria in cancer. Cancer Lett., 336: 1-7.
   CrossRef  |  
10. Besse, A., J. Sana, P. Fadrus and O. Slaby, 2013. MicroRNAs involved in chemo- and radioresistance of high-grade gliomas. Tumour Biol., 34: 1969-1978.
11. Svoboda, M., J. Sana, P. Fabian, I. Kocakova and J. Gombosova et al., 2012. MicroRNA expression profile associated with response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients. Radiat. Oncol., 7: 195-195.
    Direct Link  |  
12. Svoboda, M., J. Sana, M. Redova, J. Navratil and M. Palacova et al., 2012. MiR-34b is associated with clinical outcome in triple-negative breast cancer patients. Diagn Pathol., Vol. 7. 10.1186/1746-1596-7-31.
    CrossRef  |  
13. Strioga, M., S. Viswanathan, A. Darinskas, O. Slaby and J. Michalek, 2012. Same or not the same? Comparison of adipose tissue-derived versus bone marrow-derived mesenchymal stem and stromal cells. Stem Cells Dev., 21: 2724-2752.
    CrossRef  |  PubMed  |  
14. Slaby, O., M. Redova, A. Poprach, J. Nekvindova and R. Iliev et al., 2012. Identification of MicroRNAs associated with early relapse after nephrectomy in renal cell carcinoma patients. Genes Chromosomes Cancer, 51: 707-716.
    CrossRef  |  PubMed  |  
15. Slaby, O., J. Bienertova-Vasku, M. Svoboda and R. Vyzula, 2012. Genetic polymorphisms and microRNAs: new direction in molecular epidemiology of solid cancer. J. Cell. Mol. Med., 16: 8-21.
    CrossRef  |  PubMed  |  
16. Slaby, O., 2012. MicroRNAs in Solid Cancer: From Biomarkers to Therapeutic Targets. Nova Science Publishers, New York, ISBN: 978-1-61324-514-9, Pages: 250.
17. Sana, J., S. Hankeova, M. Svoboda, I. Kiss, R. Vyzula and O. Slaby, 2012. Expression levels of transcribed ultraconserved regions uc. 73 and uc. 388 are altered in colorectal cancer. Oncology, 82: 114-118.
    CrossRef  |  
18. Sana, J., P. Faltejskova, M. Svoboda and O. Slaby, 2012. Novel classes of non-coding RNAs and cancer. J. Transl. Med., Vol. 10. 10.1186/1479-5876-10-103.
    CrossRef  |  
19. Redova, M., A. Poprach, J. Nekvindova, R. Iliev and L. Radova et al., 2012. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J. Transl. Med., 10: 55-55.
    Direct Link  |  
20. Kren, L., P. Fabian, O. Slaby, A. Janikova and O. Soucek et al., 2012. Multifunctional immune-modulatory protein HLA-E identified in classical Hodgkin lymphoma: Possible implications. Pathol. Res. Pract., 208: 45-49.
    CrossRef  |  
21. Kren, L., I. Valkovsky, J. Dolezel, I. Capak and D. Pacik et al., 2012. HLA-G and HLA-E specific mRNAs connote opposite prognostic significance in renal cell carcinoma. Diagn Pathol., Vol. 58. 10.1186/1746-1596-7-58.
    CrossRef  |  
22. Hezova, R., J. Bienertova-Vasku, M. Sachlova, V. Brezkova and A. Vasku et al., 2012. Common polymorphisms in GSTM1, GSTT1, GSTP1, GSTA1 and susceptibility to colorectal cancer in the central European population. Eur. J. Med. Res., Vol. 17. 10.1186/2047-783X-17-17.
    CrossRef  |  
23. Hezova, R., A. Kovarikova, J. Bienertova-Vasku, M. Sachlova and M. Redova et al., 2012. Evaluation of SNPs in miR-196-a2, miR-27a and miR-146a as risk factors of colorectal cancer. World J. Gastroenterol., 18: 2827-2831.
    CrossRef  |  
24. Grell, P., P. Fabian, M. Khoylou, L. Radova and O. Slaby et al., 2012. Akt expression and compartmentalization in prediction of clinical outcome in HER2-positive metastatic breast cancer patients treated with trastuzumab. Int. J. Oncol., 41: 1204-1212.
    CrossRef  |  
25. Faltejskova, P., O. Bocanek, M. Sachlova, M. Svoboda, I. Kiss, R. Vyzula and O. Slaby, 2012. Circulating miR-17-3p, miR-29a, miR-92a and miR-135b in serum: Evidence against their usage as biomarkers in colorectal cancer. Cancer Biomarkers, 12: 199-204.
    CrossRef  |  
26. Faltejskova, P., M. Svoboda, K. Srutova, J. Mlcochova and A. Besse et al., 2012. Identification and functional screening of microRNAs highly deregulated in colorectal cancer. J. Cell. Mol. Med., 16: 2655-2666.
    CrossRef  |  
27. Faltejskova, P., A. Besse, S. Sevcikova, L. Kubiczkova and M. Svoboda et al., 2012. Clinical correlations of miR-21 expression in colorectal cancer patients and effects of its inhibition on DLD1 colon cancer cells. Int. J. Colorectal Dis., 27: 1401-1408.
    CrossRef  |  PubMed  |  
28. Faltejskova, P. and O. Slaby, 2012. Non-Coding RNAs in Gastrointestinal Cancer. LAP Lambert Academic Publishing AG and Co KG, Germany, ISBN: 978-36-5918-971-5, Pages: 104.
29. Sana, J., M. Hajduch, J. Michalek, R. Vyzula and O. Slaby, 2011. MicroRNAs and glioblastoma: Roles in core signalling pathways and potential clinical implications. J. Cell. Mol. Med., 15: 1636-1644.
    CrossRef  |  PubMed  |  
30. Redova, M., M. Svoboda and O. Slaby, 2011. MicroRNAs and their target gene networks in renal cell carcinoma. Biochem. Biophys. Res. Commun., 405: 153-156.
    CrossRef  |  PubMed  |  
31. Lakomy, R., J. Sana, S. Hankeova, P. Fadrus and L. Kren et al., 2011. MiR‐195, miR‐196b, miR‐181c, miR‐21 expression levels and O‐6‐methylguanine‐DNA methyltransferase methylation status are associated with clinical outcome in glioblastoma patients. Cancer Sci., 102: 2186-2190.
    CrossRef  |  
32. Kren, L., O. Slaby, K. Muckova, E. Lzicarova and M. Sova et al., 2011. Expression of immune-modulatory molecules HLA-G and HLA-E by tumor cells in glioblastomas: An unexpected prognostic significance? Neuropathology, 31: 129-134.
    CrossRef  |  
33. Almasi, M., S. Sevcikova, O. Slaby, P. Kaisarova and V. Maisnar et al., 2011. Association study of selected genetic polymorphisms and occurrence of venous thromboembolism in patients with multiple myeloma who were treated with thalidomide. Clin. Lymphoma Myeloma Leukemia, 11: 414-420.
    CrossRef  |  
34. Slaby, O., R. Lakomy, P. Fadrus, R. Hrstka and L. Kren et al., 2010. MicroRNA-181 family predicts response to concomitant chemoradiotherapy with temozolomide in glioblastoma patients. Neoplasma, 57: 264-269.
    PubMed  |  
35. Slaby, O., M. Sachlova, M. Bednarikova, P. Fabian and M. Svoboda et al., 2010. Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs. Cancer Biother. Radiopharm., 25: 237-243.
    CrossRef  |  PubMed  |  
36. Slaby, O., J. Jancovicova, R. Lakomy, M. Svoboda and A. Poprach et al., 2010. Expression of miRNA-106b in conventional renal cell carcinoma is a potential marker for prediction of early metastasis after nephrectomy. J. Exp. Clin. Cancer Res., 29: 90-90.
    CrossRef  |  PubMed  |  
37. Michalek, J., D. Ocadlikova, E. Matejkova, V. Foltankova and S. Dudova et al., 2010. Individual myeloma-specific T-cell clones eliminate tumour cells and correlate with clinical outcomes in patients with multiple myeloma. Br. J. Haematol., 148: 859-867.
    CrossRef  |  PubMed  |  
38. Kren, L., K. Muckova, E. Lzicarova, M. Sova and V. Vybihal et al., 2010. Production of immune-modulatory nonclassical molecules HLA-G and HLA-E by tumor infiltrating ameboid microglia/macrophages in glioblastomas: A role in innate immunity? J. Neuroimmunol., 220: 131-135.
    CrossRef  |  PubMed  |  
39. Hezova, R., O. Slaby, P. Faltejskova, Z. Mikulkova and I. Buresova et al., 2010. MicroRNA-342, microRNA-191 and microRNA-510 are differentially expressed in T regulatory cells of type 1 diabetic patients. Cell. Immunol., 260: 70-74.
    CrossRef  |  PubMed  |  
40. Slaby, O., M. Svoboda, J. Michalek and R. Vyzula, 2009. MicroRNAs in colorectal cancer: Translation of molecular biology into clinical application. Mol. Cancer, Vol. 8. 10.1186/1476-4598-8-102.
    CrossRef  |  
41. Slaby, O., K. Sobkova, M. Svoboda, I. Garajova and P. Fabian et al., 2009. Significant overexpression of Hsp110 gene during colorectal cancer progression. Oncol. Rep., 21: 1235-1241.
    PubMed  |  
42. Novakova, J., O. Slaby, R. Vyzula and J. Michalek, 2009. MicroRNA involvement in glioblastoma pathogenesis. Biochem. Biophys. Res. Commun., 386: 1-5.
    CrossRef  |  
43. Hanak, L., O. Slaby, L. Lauerova, L. Kren, R. Nenutil and J. Michalek, 2009. Expression pattern of HLA class I antigens in renal cell carcinoma and primary cell line cultures: Methodological implications for immunotherapy. Med. Sci. Monit., 15: CR638-CR643.
    PubMed  |  
44. Ovesna, J., O. Slaby, O. Toussaint, M. Kodicek, P. Marsik, V. Pouchova and T. Vanek, 2008. High throughput omics approaches to assess the effects of phytochemicals in human health studies. Br. J. Nutr., 99: ES127-34.
    CrossRef  |  PubMed  |  
45. Slaby, O., M. Svoboda, P. Fabian, T. Smerdova and D. Knoflickova et al., 2007. Altered expression of miR-21, miR-31, miR-143 and miR-145 is related to clinicopathologic features of colorectal cancer. Oncology, 72: 397-402.
    CrossRef  |  PubMed  |